PF 07224826
Alternative Names: PF-07224826Latest Information Update: 22 Nov 2023
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Nov 2023 Pfizer withdraws phase I trial prior to enrolment in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) (PO) due to business considerations (NCT05905341)
- 15 Jun 2023 Pfizer plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) (PO) in June 2023 (NCT05905341)
- 14 Jun 2023 Preclinical trials in Solid tumours in USA (PO), prior to June 2023